Decreased ζ chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma

Clinical Cancer Research

Volumn 7, Issue 11 SUPPL., 2001, Pages

  Dworacki, Grzegorz ^a   Meidenbauer, Norbert ^a   Kuss, Iris ^a   Hoffmann, Thomas K ^a   Gooding, William ^a   Lotze, Michael ^a   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN T CELL RECEPTOR, ZETA CHAIN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; DNA FRAGMENT; FAS ANTIGEN; LIPOCORTIN 5; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; BLOOD; CELL CULTURE; COCULTURE; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; LEUKEMIA CELL LINE; MELANOMA; METABOLISM; MONONUCLEAR CELL; NICK END LABELING; PATHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TIME; UPREGULATION;

ANNEXIN A5; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD56; ANTIGENS, CD8; ANTIGENS, CD95; APOPTOSIS; COCULTURE TECHNIQUES; DNA FRAGMENTATION; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; MELANOMA; MEMBRANE PROTEINS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TIME FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0035292979     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Zea, A. H., Brendan, C. D., Longo, D. L., Alvord, W. G., Strobl, S. L., Mizoguchi, H., Creekmore, S. P., O'Shea, J. J., Powers, G. C., Urba, W. J., Ochoa, A. C. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res., 1: 1327-1335, 1995.
2. Rabinowich, H., Banks, M., Reichert, T., Logan, T. F., Kirkwood, J. M., and Whiteside, T. L. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after IL-2 therapy. Clin. Cancer Res., 2: 1263-1274, 1996.
3. Maccalli, C., Pisarra, P., Vegetti, C., Sensi, M., Parmiani, G., and Anichini, A. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J. Immunol., 163: 6912-6923, 1999.
4. Reichert, T. E., Day, R., Wagner, E. M., and Whiteside, T. L. Absent of low expression of the chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res., 58: 5344-5347, 1998.
5. Rabinowich, H., Reichert, T. E., Kashii, Y., Bell, M. C., and Whiteside, T. L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of TcR in tumor-associated lymphocytes. J. Clin. Investig., 101: 2579-2588, 1998.
6. Saito, T., Dworacki, G., Gooding, W., Lotze, M. T., and Whiteside, T. L. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin. Cancer Res., 6: 1351-1364, 2000.
7. Gastman, B. R., Johnson, D. E., Whiteside, T. L., and Rabinowich, H. Caspase-mediated degradation of TCR-ζ chain. Cancer Res., 59: 1422-1427, 1999.
8. O'Connell, J., O'Sullivan, G. C., Collins, G. K., and Shanahan, F. The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
9. Shiraki, K., Tsuji, N., Shiroda, T., Isselbacher, K. J., and Takahashi, H. Expression of Fas Ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA, 94: 6420-6425, 1997.
10. Gastman, B. R., Atarashi, Y., Reichert, T. E., Saito, T., Balkir, L., Rabinowich, H., Whiteside, T. L. Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promotes apoptosis of T lymphocytes. Cancer Res., 59: 5356-5364, 1999.
11. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bomand, T., Fontana, A., Leinard, D., Cerottini, J-C., and Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 4521-4524, 1996.
12. Chappell, D. B., Zaks, T. Z., Rosenberg, S. A., and Restifo, N. P. Human melanoma cell do not express Fas (Apo-I/CD95) ligand. Cancer Res., 59: 59-62, 1999.
13. Zaks, T. Z., Chappell, D. B., Rosenberg, S. A., and Restifo, N. P. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol., 162: 3273-3279, 1999.
14. Kuss, I., Saito, T., Johnson, J. T., and Whiteside, T. L. Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin. Cancer Res., 5: 329-334, 1999.
15. Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, M. A., Lassota, P., and Traganos, F. Features of apoptotic cells measured by flow cytometry. Cytometry, 13: 795-808, 1992.
16. Gastman, B. R., Johnson, D. E., Whiteside, T. L., and Rabinowich, H. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood, 95: 2015-2023, 2000.
17. Lang, S., Atarashi, Y., Nishioka, Y., Stanson, J., Meidenbauer, N., and Whiteside, T. L. B7.1 on human carcinomas: co-stimulation of T cells and enhanced tumor-induced T-cell death. Cellular Immunol., 201: 132-143, 2000.
18. Aubry, J. P., Blaecke, A., Lecoanet-Henchoz, S., Jeannin, P., Herbault, N., Caron, G., Moine, V., and Bonnefoy, J. Y. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry, 37: 197-204, 1999.
19. Neumeister Kersh, E., Shaw, A. S., and Allen, P. M. Fidelity of T cell activation through multistep T cell receptor ζ phosphorylation. Science (Washington DC), 281: 572-575, 1998.
20. Anderson, P., Caligiuri, M., O'Brien, C., Manley, T., Ritz, J., and Schlossman, S. F. Fcγ receptor type III (CD 16) is included in the ζ NK receptor complex expressed by human natural killer cells. Proc. Natl. Acad. Sci. USA, 87: 2274-2278, 1990.
21. Donnenberg, A. D., and Margolick, J. B. T-cell homeostasis in HIV-1 infection. Semin. Immunol., 9: 381-388, 1997.
22. Hellerstein, M., Hanley, M. B., Cesar, D., Siler, S., Pagageorgopoulos, C., Wieder, E., Schmidt, D., Hoh, R., Neese, R., Macallan, D., Deeks, S., and McCune, J. M. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med., 5: 83-89, 1999.
23. Wolthers, K. C., Schuitemaker, H., and Miederna, F. Rapid CD4 T cell turnover in HIV-1 infection: a paradigm revisited. Immunol. Today, 19: 44-48, 1998.
24. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., and Davis, M. M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-685, 1999.
25. Saito, T., Kuss, I., Dworacki, G., Gooding, W., Johnson, J. T., and Whiteside, T. L. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin. Cancer Res., 5: 1263-1273, 1999.
26. Reed, J. C., Jurgensmeier, J. M., and Matsuyama, S. Bcl-2 family proteins and mitochondria. Biochem. Biophys. Acta, 136: 127-137, 1998.
27. Roy, N., Deveraux, Q. L., Takahashi, R., Slavesen, G. S., and Reed, J. C. The c-IAP-1 and cIAP-2 proteins are direct inhibitors of specific caspases. EMBO J., 16: 6914-6925, 1997.
28. Tschopp, J., Irmler, M., and Thorne, M. Inhibition of Fas death signals by FLIPS. Curr. Opin. Immunol., 10: 552-558, 1998.
29. Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V., Perrin, G., French, L., van Meir, E. G., de Tribolet, N., Tschopp, J. J., and Dietrich, P. Y. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain. J. Clin. Invest., 99: 1173-1180, 1997.
30. Mitsiades, N., Poulaki, V., Leone, A., and Tsokos, M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am. J. Pathol., 153: 1947-1956, 1998.
31. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., and Shanahan, F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol., 160: 5669-5675, 1998.
32. Whiteside, T. L., and Rabinowich, H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol. Immunother., 46: 175-184, 1998.
33. Zheng, L., Fisher, G., Combadiere, B., Homing, F., Martin, D., Pelfrey, C., Wang, J., and Lenardo, M. Mature T lymphocyte apoptosis in the healthy and diseased immune system. In: S. Gupta and S. Cohen (eds.), Mechanisms of Lymphocyte Activation and Immune Regulation, Vol. VI, pp. 229-239. New York: Plenum Publishing Corp., 1996.
34. Combadiere, B., Freedman, M., Chen, L., Shores, E. W., Love, P., and Lenardo, M. J. Quantitative and qualitative contributions of the T-cell receptor ζ chain to mature T cell apoptosis. J. Exp. Med., 183: 2109-2117, 1996.
35. Kono, K., Ressing, M. E., Brandt, R. M. P., Melief, C. J. M., Potkul, R. K., Andersson, B., Petersson, M., Kast, W. M., and Kiessling, R. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells inpatients with cervical cancer. Clin. Cancer Res., 2: 1825-1828, 1996.
36. Matsuda, M., Petersson, M., Lenke, R., Taupin, J-L., Magnusson, I., Mellstedt, H., Anderson, P., and Kiessling, R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer, 61: 765-772, 1995.
37. Kiessling, R., Kono, K., Petersson, M., and Wasserman, K. Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin. Immunopathol., 18: 227-242. 1996.
38. Whiteside, T. L. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol. Immunother., 48: 346-352, 1999.